Owlstone Medical
Owlstone Medical’s vision is to save 100,000 lives by realizing the enormous promise of breath-based diagnostics through the development and application of Breath Biopsy, a unique platform capable of both biomarker discovery and use in routine clinical testing. The platform includes ReCIVA, a proprietary sample collection device that can take stable breath samples anywhere, the world’s only commercial-scale Breath Biopsy Laboratory located in Cambridge, U.K., and the Breath Biopsy VOC Atlas, the most extensive catalogue of identified volatile organic compounds (VOCs) commonly found on breath. The Company’s technology is protected by over 160 granted and pending patents and has been used in more 100 research papers.Owlstone Medical’s Research Products and Services are being deployed at over 100 sites around the world with large pharmaceutical companies including AstraZeneca, Actelion (a J&J company), GlaxoSmithKline, and leading academic institutions. Projects are supported by Breath Biopsy OMNI®, the most advanced solution for reliable end-to-end global breath VOC analysis, which is helping researchers advance biomarker discovery and disease research and maximizing the chances of finding clinically relevant breath biomarkers. The Company has a portfolio of Breath Biopsy tests in development for the early detection of lung cancer and liver disease, both areas of high unmet clinical need that represent multi-billion dollar market opportunities. In digestive health, under the OMED Health brand, clinical tests for Small Intestinal Bacterial Overgrowth and carbohydrate malabsorption are on market in the U.K., and a handheld device and app for longitudinal monitoring of digestive health is in development.Content by Owlstone Medical
| 3 min read
The POSEIDON program aims to create first-in-class synthetic sensor-based tests to detect over 30 cancers at Stage I using only non-invasive breath and urine samples.
| 2 min read
Expanded high-value end-to-end solution positions business for rapid growth in multi-billion dollar functional GI market
Page 1 of 1 - 2 Total Items
